RFA-RM-21-008: Cellular Senescence Network: Tissue Mapping Centers (U54 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 22, 2021.
From the official notice on Grants.gov, last changed January 25, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU54
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$548,061
- Typical project length6 years
- U54, Specialized Center Cooperative Agreement. A research center with several projects and shared cores, with substantial NIH involvement. Other open U54 notices.
Projects funded under RFA-RM-21-008 were run by National Institute on Aging (NIA, 8 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-21-008 in the NIH Guide.
Key dates
| Posted | January 6, 2021 |
|---|---|
| Deadline | March 22, 2021 |
| Archived by Grants.gov | April 21, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) to work within the Cellular Senescence Network (SenNet). The goal of the SenNet consortium is to identify and functionally characterize the heterogeneity of senescent cells across multiple tissues in human health, disease, and lifespan at single-cell resolution. Through collaborative efforts, the consortium will generate a multimodal, multidimensional Atlas of senescent cells in various human tissues; develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable Atlas of Cellular Senescence, ensure the utility of the database, and promote collaboration through Network engagement with the research community. The TMCs solicited through this RFA will generate the high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the lifespan and physiological states necessary to generate the Senescence Atlas. The SenNet is focused on healthy human tissues, and work in diseased tissue or animal models is acceptable only as long as it is used to support this overall goal. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ, tissue and single cell level using omics, imaging and other approaches, to data integration, analysis and interpretation.
Funded under RFA-RM-21-008 so far
NIH funded 8 projects under RFA-RM-21-008 in fiscal 2021 to 2025, at 8 institutions. The median yearly award was $548,061.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Biological Analysis Core | Duke University | 2025 | $731,785 |
| WU-SN-TMC Bio-Analysis Core | Washington University | 2025 | $845,309 |
| Biospecimen Core | Columbia University Health Sciences | 2025 | $455,184 |
| Core D: Data Analysis Core | Yale University | 2025 | $324,645 |
| Data-Analysis-Core | University of Pittsburgh at Pittsburgh | 2025 | $512,308 |
| Biospecimen Core for Procurement of Human Somatic and Reproductive Tissues for Senescent Cell Mapping | Buck Institute for Research on Aging | 2025 | $462,450 |
| The KAPP-Sen Tissue Mapping Center Collaborative | University of Connecticut Sch of Med/DNT | 2025 | $2.7 million |
| Minnesota Tissue Mapping Center for Senescent Cells | University of Minnesota | 2025 | $1.7 million |
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-21-008 still open?
No. It closed on March 22, 2021.
Who can apply for Cellular Senescence Network: Tissue Mapping Centers (U54 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cellular Senescence Network: Tissue Mapping Centers (U54 Clinical Trial Not Allowed)?
Closed March 22, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-RM-21-008?
NIH RePORTER lists 8 projects funded under RFA-RM-21-008 in fiscal 2021 to 2025, at 8 institutions. The most were at Duke University, Washington University, Columbia University Health Sciences.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- Health and Extreme Weather Solutions-Focused Research Hubs (U54 - Clinical Trial Optional)
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
- Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed)